ADVERTISEMENT

LEGAL

Washington court says obesity insurance exclusions on Ozempic, Mounjaro may be discrimination

A Washington appeals court ruled insurers can't blanket-exclude weight-loss drugs for obesity patients, setting up a broader fight over what plans must cover.

Ozempic injection pen on a table...

Jeannette Simonton has paid out of pocket for obesity medication since 2023 after her state health plan refused to cover any prescription drugs for obesity, including Ozempic. (Photo: Jakub Porzycki/Getty Images)

(Photo: Jakub Porzycki/Getty Images)

A Washington Court of Appeals ruling last week is forcing insurance companies across the state to justify why they won’t cover weight-loss drugs for patients with obesity. The legal theory behind the case is more significant than it might first appear.

Under Washington law, obesity is a protected disability class. A 2019 state Supreme Court decision establishing that classification was aimed at employment discrimination, but a federal appeals judge has now extended its reach into insurance plan design, with potentially large consequences.

The case began with a nurse named Jeannette Simonton, who needed knee surgery in 2023 but was required to lose weight first before doctors would perform it. Her state health plan covered bariatric surgery and nutrition counseling but excluded prescription drugs for obesity entirely, including Mounjaro and Ozempic. With no coverage, Simonton has been paying $450 a month out of pocket for the lowest dose of Mounjaro, as the Seattle Times reported. As a caregiver for her disabled husband, she described that cost as a heavy burden.

What the court ruled about discrimination and obesity

A lower court threw out Simonton’s case, pointing to a state statute that explicitly allows weight-loss drugs to be medicines that health plans are “not required to include.” Court of Appeals Judge Ian Birk rejected that reasoning. He found the statute sets a minimum benefit floor and says nothing about whether excluding a drug specifically because it treats a protected disability crosses into discrimination. Birk wrote that insurers cannot deny coverage “simply because they are to treat that disability.”

ADVERTISEMENT

“To do so would discriminate because of that disability,” Birk wrote. “What the statute does not permit … is what Simonton and Kelso allege happened here — a plan’s deciding not to deal with a person’s disability for no reason other than because it had always done so.”

The ruling itself is not a victory. A lower court now has to determine whether the insurer had any legitimate rationale for the exclusion. Plans can still refuse coverage if drugs are experimental, not effective, or not cost-effective.

The discrimination argument

When the original lawsuits were first filed, MyNorthwest reported on plaintiff attorney Rick Spoonemore’s argument that the exclusion is textbook discrimination.

“The health insurer — although it covers other medically necessary drugs for other conditions — says because you are obese, we’re going to exclude coverage,” Spoonemore said. “That is straight-up unfair discrimination under (Washington) law.”

ADVERTISEMENT

University of Utah pharmacoeconomics professor Joey Mattingly told the Seattle Times that blanket exclusions on weight-loss drugs have been industry standard for years, though the landscape is shifting.

“There is definitely a longstanding precedent around weight-loss drugs not being covered,” Mattingly said. “When plans are deciding what to cover, they look at whether something is cosmetic or has a clinical purpose. Often weight-loss drugs were seen as ineffective and possibly even dangerous.”

Wegovy, made by Novo Nordisk, carries a list price of $1,349 a month. If courts ultimately require Washington plans to cover every drug prescribed for obesity, every enrolled member in the state will feel that decision in their own premiums.

Follow Seattle Red on-air at 770 AM, on the Seattle Red app, and streaming audio and video on SeattleRed.com.

Comments

0 Comments